Fifth Third Bancorp Sells 4,930 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Fifth Third Bancorp decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 97.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 127 shares of the biopharmaceutical company’s stock after selling 4,930 shares during the quarter. Fifth Third Bancorp’s holdings in Alnylam Pharmaceuticals were worth $51,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $11,389,000. Rakuten Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $14,205,000. Cerity Partners LLC lifted its position in Alnylam Pharmaceuticals by 171.2% during the third quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company’s stock valued at $12,507,000 after purchasing an additional 17,316 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Alnylam Pharmaceuticals during the third quarter valued at $5,790,000. Finally, Perpetual Ltd bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $2,004,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.3%

Shares of ALNY opened at $295.05 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $250.35 and a 1-year high of $495.55. The company has a 50-day moving average of $318.15 and a 200 day moving average of $372.43. The firm has a market capitalization of $39.39 billion, a price-to-earnings ratio of 80.61 and a beta of 0.31. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business posted ($0.44) EPS. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ALNY. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Raymond James Financial reiterated an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. HC Wainwright restated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 5th. Finally, Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $471.96.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to $7.86 from $7.31, suggesting stronger near-term profitability expectations for Alnylam.
• Positive Sentiment: The same analyst kept a Buy rating and reiterated a $510 price target, signaling continued confidence in Alnylam’s longer-term growth outlook.
• Positive Sentiment: HC Wainwright also lifted its Q2 2026 EPS estimate to $1.43 from $1.36, which is a modest short-term improvement.
• Neutral Sentiment: Several longer-dated earnings forecasts were mostly trimmed only slightly, including FY2027, FY2028, FY2029, and FY2030, which suggests only minor adjustments rather than a major change in the investment thesis.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 and Q4 2026 EPS estimates, which may have tempered enthusiasm around the company’s earnings trajectory.
• Negative Sentiment: An FDA untitled letter regarding Amvuttra survival claims may have added regulatory uncertainty and weighed on sentiment toward ALNY. FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president directly owned 59,802 shares in the company, valued at $18,543,404.16. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 38,656 shares of company stock worth $12,370,696. 0.86% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.